[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Nyrönen et al., 2001 - Google Patents

Molecular mechanism for agonist-promoted α2A-adrenoceptor activation by norepinephrine and epinephrine

Nyrönen et al., 2001

View PDF
Document ID
5661002585847861141
Author
Nyrönen T
Pihlavisto M
Peltonen J
Hoffrén A
Varis M
Salminen T
Wurster S
Marjamäki A
Kanerva L
Katainen E
Laaksonen L
Savola J
Scheinin M
Johnson M
Publication year
Publication venue
Molecular Pharmacology

External Links

Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Similar Documents

Publication Publication Date Title
Nyrönen et al. Molecular mechanism for agonist-promoted α2A-adrenoceptor activation by norepinephrine and epinephrine
Shapiro et al. Differential modes of agonist binding to 5-hydroxytryptamine2A serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5
Katada et al. Structural basis for a broad but selective ligand spectrum of a mouse olfactory receptor: mapping the odorant-binding site
Vass et al. Aminergic gpcr–ligand interactions: A chemical and structural map of receptor mutation data
Kenakin Ligand-selective receptor conformations revisited: the promise and the problem
Liapakis et al. Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the β2 adrenergic receptor
Sealfon et al. Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT2A Receptor (∗)
Kenakin Efficacy at G-protein-coupled receptors
Zürn et al. Fluorescence resonance energy transfer analysis of α2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes
Fillion et al. Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode
Gnagey et al. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors
Rossier et al. Inverse agonism and neutral antagonism at α1a-and α1b-adrenergic receptor subtypes
Qu et al. Structural basis of the diversity of adrenergic receptors
Abdul-Ridha et al. Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor
Spalding et al. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation
López-Rodrı́guez et al. Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine1a receptor ligands to explore the three-dimensional structure of the receptor
Wu et al. Probing the correlation between ligand efficacy and conformational diversity at the α1A-adrenoreceptor reveals allosteric coupling of its microswitches
Seifert et al. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities
Fowler et al. Refinement of a homology model of the μ-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites
Ishii et al. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants
Stitham et al. The unique ligand-binding pocket for the human prostacyclin receptor: site-directed mutagenesis and molecular modeling
Miura et al. Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane Helix-2
Cawston et al. Molecular basis for binding and subtype selectivity of 1, 4-benzodiazepine antagonist ligands of the cholecystokinin receptor
Liu et al. Alternative pre-mRNA splicing of the mu opioid receptor gene, OPRM1: insight into complex mu opioid actions
Straßer et al. Pharmacological profile of histaprodifens at four recombinant histamine H1 receptor species isoforms